Abstract 31P
Background
Pathological complete response (pCR) is the strongest patient-level prognostic factor in patients with early triple-negative breast cancer (TNBC) undergoing neoadjuvant chemo-immunotherapy (NAT). Blood-based biomarkers have been proposed to recapitulate the immune-milieu and to anticipate benefit from NAT. We explored correlations between pCR and immune-inflammatory indices such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), granulocyte-stimulating factors (G-CSF) use, all having demonstrated to be prognostic in the metastatic setting.
Methods
We retrospectively collected data from all consecutive patients who completed NAT with pembrolizumab (KEYNOTE-522 regimen) from Jan 2022 until Aug 2024, from our single-institution cohort. Logistic regression was performed to investigate the association between pCR and NLR or PLR at baseline (0), at the switch from taxane-to anthracycline-based chemo (5) and at the end of the NAT (8). Odds ratios (OR), 95% confidence intervals (CI), and p-values were calculated with alpha set at 0.05.
Results
Of the 43 patients included in the study, 49% were diagnosed with stage IIB, achieving a pCR in 61% of these cases. The OR for the NLR0 was 0.90 (95% CI: 0.57–1.42, p=0.665), for NLR5 was 0.74 (p=0.190) and for NLR8 was 0.86 (p=0.421), indicating no significant predictive value for pCR. Similarly, PLR0 (OR: 0.99, p=0.623) and PLR5 (OR: 0.99, p=0.139) also showed no significant association; the use of G-CSF was not independently prognostic. When examining combined models including G-CSF and NLR values, no statistical significance was observed; the combination of G-CSF and NLR5 yielded an OR of 0.72 (95% CI: 0.45–1.16, p=0.184).
Conclusions
Our research evaluated the longitudinal trend of NLR or PLR in the NAT setting. We did not find evidence to support the use of NLR or PLR (at different timepoints) as predictive biomarkers of pCR with NAT in patients with early TNBC, mainly due to the low statistical power. Future studies with larger sample sizes and additional biomarkers may be necessary to identify robust and reliable predictors of treatment response.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
54P - Superior antitumor activities of fourth-generation CAR-T cells containing three costimulatory domains targeting GD2-positive tumors
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
Resources:
Abstract
55P - Engineering of chimeric cytokine receptors (CCR) to induce IL-7 signaling to CAR-T cells for solid tumor treatment
Presenter: Marta Soria Castellano
Session: Poster Display session
Resources:
Abstract
56P - Potent antitumor efficiency of CD19-CAR T cells self-secreting PD-L1 x CD3 BiTE against aggressive B-cell lymphoma
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
Resources:
Abstract
57P - SENDER™ Directed LNP Delivery of mRNA for In Situ generation of highly potent CAR T Cells
Presenter: Biao Ma
Session: Poster Display session
Resources:
Abstract
58P - Cardiovascular outcomes of novel CAR-T cell therapies: A meta-analysis of incidence, risk factors, and management of cardiotoxicity
Presenter: Hashim Talib Hashim
Session: Poster Display session
Resources:
Abstract
59P - Long term survival data from all recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients treated with MVX-ONCO-1 during open-labelled phase I and phase IIa clinical trials
Presenter: Nicolas Mach
Session: Poster Display session
Resources:
Abstract
60P - Innovative applications of neoantigens in dendritic cell-derived exosome (DEX) therapy and their impact on personalized cancer treatment
Presenter: Ramon Gutierrez
Session: Poster Display session
Resources:
Abstract
61P - Optimized protocol for the accelerated production of dendritic cell-derived exosomes (DEXs): Achieving speed without compromising efficacy
Presenter: Ramon Gutierrez
Session: Poster Display session
Resources:
Abstract
62P - Ecto-CRT induction of NKp46 surface expression increases osimertinib-resistant lung cancer’s sensitivity to NK cells
Presenter: Sumei Chen
Session: Poster Display session
Resources:
Abstract
63P - Single-cell RNA-seq combined with bulk RNA-seq revealed the involvement of pancreatic cancer tissue-resident macrophages in tumour progression and the immunotherapy response
Presenter: Bin Wu
Session: Poster Display session
Resources:
Abstract